Research Expert: Sarah Overall
  • Published: Jun 2025
  • Pages: 150
  • SKU: IRTNTR75007

  • Latest News- Hospital Infection Therapeutics Market: Antibiotics drugs is expected to lead the Drug Class segment during 2025-2029

    The Hospital Infection Therapeutics Market is being driven by Increase in incidence and prevalence of respiratory disorders

    The Hospital Infection Therapeutics Market is expected to grow at a CAGR of 5.5% during 2024 and 2029. During this period, the market is also expected to show a growth of USD 3786.3 million. The global rise in chronic diseases is driving an increase in hospital patient visits, leading to a corresponding surge in the prevalence of healthcare-associated infections (HAIs). Central venous catheters, a common medical device used in hospitals, are a significant contributor to HAIs. It is projected that their usage will expand by 8% by 2025, heightening the risk of hospital infection diseases. Hospitals serve as a significant source of infections, resulting in increased morbidity and mortality among hospitalized patients. Intensive Care Units (ICUs), in particular, are susceptible to infections due to the high number of invasive, therapeutic, and diagnostic procedures performed there. Sepsis, a severe complication of hospital infection diseases, poses a significant threat to patient health. 

    Get more information on Hospital Infection Therapeutics Market by requesting a sample report

    Which Factors Are Causing a Surge in Market Growth?

    The market is segmented based on

    • Drug Class
      • Antibiotics drugs
      • Antifungal drugs
      • Antiviral drugs
    • Type
      • Respiratory tract infections
      • Surgical site infections
      • Bloodstream infections
      • Gastrointestinal infections
      • Urinary tract infections
    • End-user
      • Hospitals
      • Ambulatory surgical centers
      • Specialty clinics
      • Long-term care facilities
    • Geography
      • North America
        • Canada
        • US
      • Europe
        • Germany
        • UK
        • France
        • Italy
      • Asia
        • China
        • India
        • Japan
        • South Korea
      • Rest of World (ROW)

      According to Technavio, There are several factors that are causing the market to flourish during the forecast period, which are as follows: 

      • Increase in incidence and prevalence of respiratory disorders
      • Growing geriatric population
      • Special drug designations

      However, the market also witnesses some limitations, which are as follows:

      • Stringent regulations
      • High cost of therapeutics
      • Development of antibacterial resistance

      Benefits of Buying Global Hospital Infection Therapeutics Market Research Report by Technavio

      Rich Experience: 20+ years leading global market research, trusted insights across industries.

      Unlock Business Potential with Technavio: Maximize ROI with Technavio's tailored market research: deep dives and actionable insights.

      Your Guide to Market Success: Empower your business with Technavio's market research and future-proof your decisions.

      Market Scope in Hospital Infection Therapeutics Market Research Report

      Market Scope

      Report Coverage

      Details

      Page number

      231

      Base year

      2024

      Historic period

      2019-2023

      Forecast period

      2025-2029

      Growth momentum & CAGR

      Accelerate at a CAGR of 5.5%

      Market growth 2025-2029

      USD 3786.3 million

      Market structure

      fragmentation

      YoY growth 2024-2025(%)

      5.1

      Key countries

      US, Germany, Canada, China, France, UK, Japan, India, Italy, South Korea, US, Germany, China, France, and UK

      Competitive landscape

      Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks

      Find out which segment is leading the market by accessing the free PDF report

      Research Analysis Overview

      The Hospital Infection Therapeutics Market focuses on combating antibiotic-resistant bacteria such as Vancomycin-Resistant Enterococci (VRE), Clostridium Difficile, Carbapenem-Resistant Enterobacteriaceae (CRE), Acinetobacter Baumannii, and Pseudomonas Aeruginosa. Solutions include biofilm disruptors, antimicrobial coatings, and antimicrobial surfaces. Surveillance systems, molecular diagnostics, rapid diagnostics, and point-of-care testing are essential for early detection. Whole genome sequencing, data analytics, AI, and machine learning aid in understanding and addressing antibiotic resistance. Precision and personalized medicine, stewardship programs, patient education, and healthcare worker education promote effective treatment. Infection control audits and quality improvement initiatives ensure patient satisfaction and positive healthcare outcomes.

      Market Research Overview

      The global Hospital Infection Therapeutics Market encompasses businesses involved in the research and development (R&D) or manufacturing of antimicrobial agents, including antibacterial drugs, antiviral drugs, and anti-fungal drugs. According to Technavio, the size of the global pharmaceuticals market is determined by the consolidated revenue generated by providers of equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services. Factors driving the growth of this market include the increasing aging population, with predictions that by 2050, approximately one-quarter of the US and European populations will be over 60 years old, leading to a higher prevalence of healthcare-associated infections (HAIs) and hospital-acquired infections (HAIs). These infections necessitate the use of antimicrobial agents and other therapeutics, thereby fueling market expansion.. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.


      Contacts

      Technavio Research
      Jesse Maida
      Media & Marketing Executive
      US: +1 844 364 1100
      UK: +44 203 893 3200
      Email: media@technavio.com
      Website: www.technavio.com/

      Read News Read Less
      Interested in this report?
      Get your sample now!

    Safe and Secure SSL Encrypted

    Technavio

    • 2500 USD

    [5 reports/month/user]

    • 5000 USD

    close
    • Basic Plan [5000 USD/Year]:

      Single User
      Download 5 Reports/Month
      View 100 Reports/Month
      Add upto 3 Users at 625 USD/user

    • Teams Plan [7500 USD/Year]:

      5 User
      Download 5 Reports/Month/User
      View 100 Reports/Month/User
      Add upto 30 Users at 500 USD/user

    *You can upgrade to Teams plan at Subscription page

    close
    • Single:

      One user only.
      Quick & easy download option

    • Enterprise:

      Unlimited user access (Within your organization).
      Complimentary Customization Included

    *For Enterprise license, go to checkout page

    Technavio Get the report (PDF) sent to your email within minutes.